{"id":"W4378952054","doi":"10.3324/haematol.2023.282781","title":"Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Jazz Pharmaceuticals; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; Amgen; StemCyte; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Department of Health and Human Services","keywords":"Medicine; Population; Confidence interval; Transplantation; Internal medicine; Aplastic anemia; Standardized mortality ratio; Hematopoietic stem cell transplantation; Hematopoietic cell; Surgery; Haematopoiesis; Bone marrow; Stem cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002098116,0.0002342283,0.0006148002,0.0001055089,0.0001022422,0.00001684058,0.0000630469,0.0001399596,0.001043495],"category_scores_gemma":[0.00004348098,0.0001642922,0.00006419612,0.0002491157,0.0001857123,0.0001017268,0.00001883043,0.0001240975,0.00003756714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000358445,"about_ca_system_score_gemma":0.00009173324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001144227,"about_ca_topic_score_gemma":0.00003658229,"domain_scores_codex":[0.9981186,0.0001535838,0.000457486,0.0003553509,0.0006511531,0.000263822],"domain_scores_gemma":[0.9987341,0.0004984371,0.0001983846,0.0002225484,0.0002424957,0.0001040318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01391628,0.0003866679,0.9748685,0.003268759,0.0002569379,0.0003746697,0.00275167,0.00004222397,0.003818187,0.0001703412,0.00009669305,0.0000490096],"study_design_scores_gemma":[0.007862046,0.0004988317,0.9743845,0.0004301385,0.0002883857,0.0001149751,0.0004646446,0.00002561789,0.01560728,0.00008259201,0.00001016466,0.000230797],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967363,0.00005905283,0.0009543928,0.0000489947,0.00007423767,0.0009118487,0.000657507,0.00009491845,0.0004627108],"genre_scores_gemma":[0.9978579,0.0002736348,0.0004844443,0.00002594364,0.00001510861,0.00007259466,0.001126044,0.00002974652,0.0001145914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0117891,"threshold_uncertainty_score":0.9998697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02402665173448778,"score_gpt":0.2587644458449191,"score_spread":0.2347377941104314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}